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Abstract
There have been over 100 randomized clinical trials (RCTs) of diverse regimens of antiretroviral therapy for treatment-na€ıve human
immunodeﬁciency virus-positive patients. A further 400 systematic reviews and meta-analyses are informed by these trials. There are,
however, difﬁculties in using systematic reviews and meta-analyses of this clinical evidence to inform guidelines and clinical practice. Several
issues canmake the interpretation of comparative effectiveness challenging. In this article, we review the key challenges in interpreting multiple
trials in this population. We speciﬁcally examine the network geometry of the clinical trial comparisons, the predominance of non-inferiority
trial designs, issues related to potential class effects, heterogeneous documentation of adverse events, and a relative lack of RCTs that reﬂect
speciﬁc current clinical guideline recommendations. We conclude with recommendations for future clinical trials and meta-analyses.
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Introduction
Antiretroviral therapy (ART) for human immunodeﬁciency
virus (HIV) infection has revolutionized how HIV is treated and
how care is provided to populations around the world [1]. The
documentation of survival beneﬁts from combination triple
therapy ART in 1996 led to a downturn in mortality from HIV
infection worldwide [2]. Subsequently, the President’s Emer-
gency Plan for AIDS Relief (PEPFAR) in 2003 marked the
largest roll-out of a drug-based intervention around the world
[3]. Because ART reduces the amount of virus in compart-
ments relevant for transmission, such as blood, semen, and the
genital tract [4], and can therefore reduce transmission of the
virus [5], many political and scientiﬁc leaders are now
postulating the prospect of an AIDS-free generation [6].
There are now 28 antiretroviral drugs on the market, and
these are typically classiﬁed according to their drug class. The
six primary drug classes are: nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs); non-nucleoside reverse
transcriptase inhibitors (NNRTIs); protease inhibitors (PIs);
integrase inhibitors (IIs); and entry inhibitors (CCR5 agents
and fusion inhibitors). Antiretroviral agents are available
individually or as ﬁxed-dose combinations, i.e. multiple
antiretroviral drugs within a single pill. ART can vary from
multiple individual drugs taken multiple times a day to a single,
once-daily pill. More than 9 000 000 people are now
receiving ART, and the yearly price of ART varies from
$300 (and decreasing) per person in PEPFAR programmes to
more than $24 000 in the USA, depending on the choice of
drug [1,7].
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Since 1996, several ART drugs have come and gone (e.g.
zalcitabine and standard-dose ritonavir) in clinical practice. The
reasons why drugs may become unfavoured are hetero-
geneous, but include unfavourable risk proﬁles, poor levels of
viral suppression, unfavourable resistance proﬁles, and com-
plex dosing schedules. For example, zalcitabine, of the NRTI
class, was discontinued in 2006 because of its frequent serious
adverse events, including peripheral neuropathy in up to 34%
of patients [8], and the inconvenience of needing to be
ingested every 8 h. As newer ART drugs have not had the
beneﬁt of time to evaluate them, it seems likely that several of
the newer agents will also be set aside as we develop a better
understanding of their clinical proﬁle and tolerability.
Given the widespread use of ART and the important
individual and public health implications of its use, we should
expect that the available clinical trial evidence supporting their
use and informing guidelines would be robust. WHO, Inter-
national AIDS Society (IAS), US Department of Health and
Human Services and European AIDS Society guidelines are
carefully revised on a frequent basis, and may inﬂuence the
clinical treatment of millions of patients. However, even more
successes could be achieved if the clinical trials conducted in
this ﬁeld built on the already accumulated clinical evidence and
avoided pitfalls. In an initial search of the published literature
on randomized clinical trials (RCTs) of ART for ART-na€ıve
adult patients, we identiﬁed 98 RCTs published as full-text
articles since 2002, the turning point when ART began to
become widely available in low-income and middle-income
countries (details of the search strategy and screening process
are available from the authors). Fig. 1 shows the numbers of
RCTs and systematic reviews (with or without the inclusion of
meta-analyses) published per year. These trials have informed
>400 systematic reviews (many of them also including formal
meta-analyses) over this period. This initially looks like an
impressive amount of clinical evidence for one speciﬁc
condition. However, upon closer inspection, the accumulated
evidence leaves much to be desired, as addressed in this
review.
Currently, sales of these drugs are led primarily by guideline
endorsements, and, perhaps less than in other ﬁelds, by
marketing to physicians and directly to patients. HIV/AIDS,
more than any other ﬁeld, has had a strong advocacy alliance of
patient groups and representatives demanding access to drugs
and advocating for early approvals and reduced prices. Such
advocacy has successfully reduced the price of treatment for
an average patient in Africa (including laboratory support), for
example, from c. $10 000 per year in 2002 to c. $300 per year
or less in PEPFAR programmes [7]. Perhaps, if the same level
of advocacy can now be applied to the conduct and sharing of
clinical trial data, the evidence needed to safely and effectively
treat long-term HIV infection may allow much improved
outcomes for patients.
Patients, clinicians and regulators want different types of
evidence to make decisions. Patients and clinicians want to
know which regimen is most effective and most safe for each
individual having to undergo life-long treatment; regulators
such as the US Food and Drug Administration and the
European Medicines Agency want to ensure that treatment
effects are well documented; and the pharmaceutical industry
wants to provide the best return for its investors. Each group
vigorously argues for its interests, and, ultimately, each group
must compromise to a certain extent. Ostensibly, such strong
advocacy by the groups means that they keep each other
accountable. However, strongly held views have, at times,
prevented access to effective treatments. When the large
conglomerate of pharmaceutical companies refused to reduce
drug prices in Africa in 2000, patient and clinical groups took
legal action to ensure access to drug treatments in South
Africa [9]. The pharmaceutical industry quickly realized that
addressing patient and physician needs would become a
necessary component of future business. If the ﬁeld of HIV/
AIDS care is to advance rapidly, relevant clinical trials that
FIG. 1. The number of randomized clinical trial (RCT) and systematic
review/meta-analysis publications pertaining to antiretroviral therapy
(ART) for the treatment of human immunodeﬁciency virus (HIV)
treatment-na€ıve adults. We searched ten electronic databases (MED-
LINE via PubMed, Cochrane CENTRAL, EMBASE, CINAHL, AMED,
PsychINFO, Clincaltrials.gov, HIV drug resistance database, Global
Health, and Web of Science) for randomized trials of individual ART by
using the search terms ‘MESH agents, antiretroviral’, ‘MESH HIV’,
‘MESH Acquired immunodeﬁciency syndrome’, ‘random*’, and ‘na€ıve
or initial or early’. We searched for systematic reviews by using the
same search terms with the addition of ‘systematic review OR
meta-analysis’, and used the Pubmed Clinical Query search ﬁlter for
systematic reviews.
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address the needs of all groups are required. Herein, we
highlight some of the key shortcomings and challenges relating
to the available clinical trial evidence on the use of ART. We
do so within the context of how clinical trials are used within
systematic reviews, in particular reviews and meta-analyses
that examine the entire evidence concerning randomized
comparisons between different types of regimen. We show
how an evaluation of the geometry of the accumulated
evidence [10–12] and meta-analyses that combine all of this
evidence (network meta-analyses) [13–15] might facilitate the
identiﬁcation of an approach to future clinical trials that
produces the most useful evidence to inform guidelines.
The Network Geometry of RCTs
Typically, as the number of treatments available for a condition
grows, so do the challenges in conducting systematic reviews
from which rigorous conclusions may be drawn. For example,
one of the mechanisms leading to poorer conclusions in the
presence of more treatments is the often inevitable paucity of
head-to-head trials between comparators of interest. ART,
sometimes referred to as combination ART, is by deﬁnition, a
combination of antiretroviral drugs. In addition to aspects of
treatment such as synergistic blockage of HIV, and variations in
dosage and pill burden - the simple, mathematical rules of
permutations dictate that combinations of three or more
drugs, with different mechanisms for blocking HIV replication,
among more than 28 drugs lead to hundreds of possible
combinations. One manner in which HIV researchers, and
reviewers of the literature in particular, have managed to deal
with this issue is to use drug classes to reduce the number of
comparisons. However, the use of drug classes has shortcom-
ings of its own, and these are discussed below.
Fig. 2 shows two networks of comparisons, both based on
the 98 RCTs involving treatment-na€ıve, adult patients that we
have identiﬁed since 2002. The stark difference between the
two networks based on the same collection of RCTs illustrates
the aforementioned complexities of combination therapy.
Fig. 2a shows comparisons across ART classes, with ART
(a)
(b)
FIG. 2. Network of viral suppression
comparisons for randomized clinical trials
(RCTs) among treatment-na€ıve human
immunodeﬁciency virus (HIV)-positive
adults. Each treatment is represented by
a circle, and lines between the circles
represent comparisons that exist in the
network of RCTs. (a) Pertains to all
regimens according to drug classes. (b)
Pertains to all backbone combinations
compared within RCTs. Each of these
nodes includes a third agent, not shown in
the ﬁgure. In 75% of cases the agent is
efavirenz, but in some cases the agent is a
protease inhibitor. ABC, abacavir; AZT,
zidovudine; ddI, didanosine; d4T,
stavudine; FI and CCR5, fusion inhibitors;
FTC, emtricitabine; II, integrase inhibitor;
II/c, cobicistat-boosted integrase inhibitor;
NNRTI, non-nucleoside reverse
transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI,
protease inhibitor; PI/r, ritonavir-boosted
protease inhibitor; 3TC, lamivudine; TDF,
tenofovir.
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classes deﬁned by the combinations of drug classes within
them (e.g. NNRTI + 2 NRTIs is the ART class composed of
regimens with a single drug from the NNRTI drug class and
two drugs from the NRTI drug class). Although there are 98
trials, only 58 inform the ART class network. The remaining 40
trials compare regimens within the same class (e.g. a trial
comparing efavirenz as a third drug with nevirapine as a third
drug, both NNRTI drugs). Such comparative trials from an
antiviral drug perspective become ‘endonodal’, or non-com-
parative, with respect to ART classes. Fig. 2b shows compar-
isons across backbones, the NRTI component of an ART
regimen. This network was restricted to only 24 RCTs. This
reﬂects the dominating interest in the third potent agent as the
crux of ART research. To this point, 15 trials even allowed
multiple backbones, implying that they were considered to be
exchangeable. In this network, the third agent was efavirenz in
18 (75%) of trials, and nevirapine and boosted saquinavir,
lopinavir, nelﬁnavir and atazanavir in the remaining trials.
The ART class network (Fig. 2a) is dominated by the
triangle composed of NNRTI + 2 NRTIs, PI + 2 NRTIs, and
PI/r + 2 NRTIs, with PI/r referring to protease inhibitors
boosted with ritonavir. The fourth most frequent node
comprises the triple-NRTI regimens, which are no longer
used in non-resource limited settings, owing to higher risks of
drug failure than with other regimens. This can all be directly
traced back to treatment guidelines. By 2002, the evidence
supporting the use of ritonavir to boost PI regimens had only
begun to be published [16]. Nonetheless, the 2002 Interna-
tional Antiviral Society-USA (IAS-USA, formerly the IAS)
guidelines already included these as a ﬁrst-line regimen, along
with single-PI regimens and NNRTI regimens [17]. By 2003,
the US Department of Health and Human Services and WHO
guidelines had already prioritized PI/r regimens over PI
regimens, owing to convincing data on the superiority of
ritonavir-boosted PIs over unboosted PIs [18]. Nonetheless,
NNRTI regimens were preferred within the WHO guidelines,
given the problems of using PI/r drugs in resource-limited
settings, because of their higher cost. Both sets of guidelines
recommended triple-NRTI regimens as an alternative ﬁrst-line
regimen to avoid signiﬁcant drug interactions. Guidelines have
been updated regularly, but NNRTI and PI/r regimens and,
more recently, II regimens are the current standard of care.
Changes from 2002 to the present principally pertain to the
choice of backbone drugs, with the IAS-USA naming tenofovir
with entricitabine as the preferred ﬁrst-line backbone, and
abacavir with lamivudine as the alternative ﬁrst-line backbone
[19]. The WHO recommendations are more sensitive to
prices, in order to accommodate resource-limited settings.
For this reason, didanosine and stavudine have long been
recommended by the WHO. Today, the WHO recommends
either zidovudine with lamivudine, or tenofovir with lamivu-
dine or entricitabine, but still recognizes stavudine as a viable
option where economic constraints exist [20].
HIV clinical trials constitute a fast-moving ﬁeld that has
adapted relatively well to changing standards of care. The
additional nodes within the ART class network can be
categorized as follows: older regimens; newer regimens using
new classes of third agents; and NRTI-sparing regimens. Strict
placebo trials have long been set aside, for obvious reasons,
and the geometry of the network shows that most new
experimental regimens are being compared with both PI/r and
NNRTI standard of care regimens. It is of note that, owing to
the dramatic progress in the development of potent, long-act-
ing and better-tolerated antiretroviral drugs, new drugs are
increasingly being tested in head-to-head comparison with the
most recently licensed competitor drug. This may eventually
lead to negative co-occurrence patterns in trial networks,
where the newest drugs are no longer compared with older
ﬁrst-generation or second-generation antiretroviral drugs
[21]. Head-to-head comparisons with both standard of care
regimens are necessary to determine with higher certainty the
relative merits of different regimens.
Several of the satellite nodes (nodes with lower centrality
scores) [21] are restricted to comparisons with only a single
standard of care regimen. Most of these are recent, such as the
NRTI-saving ARTs PI/r + CCR5 and PI + II, and one would
accept that more comparisons will follow if these are to
become acceptable alternatives. However, one of these
satellite nodes is the regimen comprising raltegravir with
tenofovir and emtricitabine (II + 2 NRTIs). As of 2012, the
IAS-USA has included this regimen as one of its four preferred
ﬁrst-line regimens [19]. Although this indicates the speed with
which the HIV medical community communicates guidance, as
alluded to earlier, it also gives pause for thought, as current
evidence is limited with regard to properly understanding
when to favour an II regimen over a PI/r regimen. Hopefully,
the planning and conduct of superiority trials will answer these
questions.
Non-inferiority Trials
Many trials conducted in the HIV population are loosely
deﬁned as non-inferiority designs. Ideally, the objective of
non-inferiority trials is to demonstrate that an experimental
treatment is not substantially worse than an active control
[22]. This is achieved by demonstrating that the lower bound
of the CI for the estimated effect of the experimental
treatment lies above the non-inferiority margin, a prespeciﬁed
cut-off below the effect of the active control [22]. In designing
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head-to-head trials, researchers must decide whether to test
for superiority or non-inferiority. Non-inferiority trials, in
most cases, require smaller sample sizes than actively
controlled superiority trials [23]. The smaller sample size
coupled with the innate uncertainty over whether superiority
can be established can render non-inferiority trials more
appealing to sponsors. Indeed, in some contexts, the sample
size required for a superiority test may not be feasible.
Nonetheless, in order for the ﬁeld to progress, non-inferiority
trials that show promise regarding improved treatment should
be followed by the appropriate superiority trials.
Among the 98 RCTs pertaining to ﬁrst-line ART, 42 (43%)
were described as non-inferiority trials. Several more reached
conclusions on similarity based on the proximity of estimated
effects rather than through a formal test. In fact, even among
those described as non-inferiority trials, not all were appro-
priately powered. A turning point appears to have occurred in
2008, from which time 35 of 59 trials (59%) were described as
either non-inferiority or equivalence trials. One criticism made
of these study designs is the arbitrary nature of the non-infe-
riority margin [24]. In this regard, the ﬁeld of ART research
appears to be rather consistent, as 80% of trials employed a
non-inferiority margin between 10% and 13% for the outcome
of viral suppression. The latter proportion excludes studies
that used time-to-suppression analyses, because bounds were
set on hazard ratios, which were typically set to c. 0.7. An
additional point of contention with respect to non-inferiority
studies is the application of intention to treat (ITT) vs.
per-protocol analyses [25]. A high dropout rate makes it easier
to conﬁrm non-inferiority in ITT analysis and may lead to
spurious conclusions. Nevertheless, 59% of these trials used
ITT only, and 24% of trials reported both ITT and per-protocol
results. High dropout rates may prevent inferior regimens
from being identiﬁed as such.
These non-inferiority trials were observed across all types
of trial, but they were more common among those comparing
drugs within a class and those comparing experimental
regimens with the standard of care. Only a single trial including
IIs was a superiority trial, which is concerning given the
inclusion of II + 2 NRTIs as a preferred ﬁrst-line regimen.
Other trials were either inferiority trials or dose-ranging trials.
The predominance of non-inferiority trials may easily be
misinterpreted, by researchers and physicians, to imply
equivalence, adding another degree of difﬁculty to the
interpretation of systematic reviews in this ﬁeld. However,
non-inferiority and equivalence are quite different in their trial
methodologies, as equivalence trials may also have to demon-
strate bio-equivalence from a pharmacokinetic perspective, or
demonstrate that both the upper and lower bounds of CIs are
within strict, predetermined boundaries [24].
Surrogate Markers
Multiple outcome measures are used within ART trials,
particularly with respect to harms and adverse events (safety
outcomes). For efﬁcacy, a few outcomes dominate. Ultimately,
the objective of ART is to enable progression to good health
and prevent HIV-related morbidity and mortality. The patho-
physiological theory of HIV dictates that high viraemia leads to
deterioration of the immune system, in turn leading to disease
progression, and ﬁnally to death [26], although systematic
evaluations of this have been inconsistent [27,28]. Although
the traditional patient-important outcomes for HIV treatment
are death and AIDS-deﬁning illness (ADI), viral suppression is a
surrogate marker for these outcomes. Almost all of the HIV
trials studied in our review used viral suppression as a primary
outcome. Studies using other primary outcomes tended to be
secondary analyses focusing on speciﬁc aspects of safety, such
as lipid proﬁles. Although viral suppression is extremely
relevant, it should be accompanied by results on mortality
and ADI. Regrettably, 29 (30%) trials failed to report on
mortality and 50 (51%) trials failed to report on progression to
new ADI over the course of the study period. This lack of
transparency with respect to patient-important efﬁcacy out-
comes necessitates substantial assumptions by end-users.
Long-term observational data can only partly ﬁll this evidence
gap.
Class Effects
As mentioned previously, most drugs used for HIV fall within
one of six drug classes. Guideline committees discuss the
recommendations for speciﬁc combinations of ART as ﬁrst-
line therapies according to their classes, and may not always
specify individual drugs within those classes. For example, the
current IAS-USA 2012 guidelines recommend two NRTIs and
a potent third agent from the NNRTI, PI/r or II class [19].
However, as acknowledged by these guideline committees,
class effects may be a misleading term, as there are clear
differences in the efﬁcacy and safety of individual drugs within
classes.
Determining whether a drug exerts a class effect is
complicated, and should extend beyond whether a drug is
biologically similar to another according to our limited
understanding of how drugs actually work. Guidance for
assessing whether a drug is exhibiting a class effect has recently
become available in the Users’ Guide to the Medical Literature
series, and extends beyond the biological make-up or action of
a drug to examine whether the therapeutic effects of drugs are
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usefully similar and whether the safety and therapeutic effects
of each drug are similar [29]. Box 1 shows considerations for
assessing class effects, and then answers these questions by
using the example of NRTI drugs.
BOX 1 Users’ Guide questions to assess whether a drug is
showing a class effect [29]
Are the agents biologically similar?
There are seven NRTIs currently available: abacavir; didanosine;
emtricitabine; lamivudine; stavudine; tenofovir; and, zidovudine.
All of these therapies revolve around inhibiting the reverse transcrip-
tase enzyme, an enzyme that is necessary to HIV-1 to complete its life
cycle.
Is potentially compelling evidence available?
What is the geometry of evidence for your evaluation?
Fig. 2b shows the network geometry of the class according to RCT
evidence. It shows a largely star-shaped network, with zidovudine and
lamivudine as the most common standard of care.
Are head-to-head comparisons warranting high conﬁdence
available?
As the head-to-head evidence is largely directed at zidovudine + lam-
ivudine, as well as ﬁve other head-to-head comparisons, our
conﬁdence is moderate. This network is moderately well connected.
How can we use indirect evidence?
Because the network is connected, and most comparisons are
ﬁrst-order links, indirect evidence probably yields compelling evidence
for comparative effects.
Are the endpoints in RCTs important to patients?
The endpoint used in this evaluation is viral suppression, a widely used
surrogate endpoint.
What are the results?
Do the numbers of trials testing each agent differ?
The number of trials range from one head-to-head comparison (e.g.
zidovudine + lamivudine + abacavir vs. zidovudine + lamivudine) to
ﬁve head-to-head comparisons (entricitabine + tenofovir vs. zidovu-
dine + lamivudine).
Are treatment effects similar across agents?
To clarify whether the drugs within the NRTI class show similar
treatment effects, we conducted a Bayesian ﬁxed-effect network
meta-analysis of all NRTI trial arms (details available from authors). We
extracted the proportion of individuals who were virally suppressed
after 48 weeks on treatment, a primary outcome for most RCTs.
Results from the analysis support changes that have been made in the
guidelines over the years. First, all common backbones had higher odds
of leading to viral suppression than the didanosine + stavudine
backbone, the strongest effect being seen with entricitabine + tenofo-
vir, with an OR of 1.91 (95% credible interval (CrI) 1.44–2.54). On the
ﬂipside, most backbones had statistically signiﬁcant odds of being
inferior to entricitabine + tenofovir, the current recommended back-
bone in resource-rich settings. It is of note that zidovudine + lamivu-
dine had two-thirds the odds of leading to viral suppression (OR 0.67;
95% CrI 0.55–0.81) of entricitabine + tenofovir. As this analysis dem-
onstrates, although it may be attractive to group all of these drugs into
a single class, for the sake of simplicity, differences in efﬁcacy may lead
to misleading inferences in reviews.
Would the addition of sufﬁciently powered evidence change the
results of direct or indirect evidence?
The results would probably change in some ways. For example,
didanosine + stavudine vs. zidovudine + lamivudine is currently show-
ing an OR of 0.79 (95% CI 0.62–1.01). This might become conven-
tionally statistically signiﬁcant if more data were available.
Are adverse events similar across agents?
Adverse events show important differences across agents. For
example, tenofovir has been associated with kidney injury, and
stavudine is rarely prescribed in developed settings, because of
neuropathy and lipodystrophy.
What are the overall quality and limitations of the evidence?
The overall quality of the evidence suggests that NRTIs may have
similar mechanisms of action; however, their treatment effects and
adverse event proﬁles suggest that they have important differences. As
a result, recommending NRTIs on the basis of class alone may be
clinically suboptimal.
Limited and Inconsistent Reporting of Harms
Although the efﬁcacy of ART has now been established in a
large number of trials, much remains to be done regarding the
determination of comparative safety proﬁles and the relative
risk of different harms with different regimens. As the HIV
patient population is surviving for longer, the prevalence of
illnesses and conditions common in those of older age is
becoming of greater interest [30]. For that reason, even
modest cardiovascular and cancer risks may result in an
important burden of clinical events. The Data collection on
Adverse events of Anti-HIV Drugs (DAD) has previously
demonstrated that use of the ﬁrst-generation PIs indinavir and
lopinavir and of the NRTIs abacavir and didanosine is
associated with an increased risk of myocardial infarction
independently of ART-induced changes in lipid proﬁles [31].
Most RCTs investigating the efﬁcacy of ARTs have
durations between 6 months and 2 years. However, serious
cardiovascular events and cancers often take much longer to
emerge, and the number of these events observed in current
RCTs will therefore be low. In such situations, no single
RCT will be able to detect a difference in safety proﬁles
between two or more treatments, but meta-analysis or
network meta-analyses of several RCTs, in addition to
well-conducted cohort studies, might. For this reason, it is
important that all rare, major clinical outcomes are reported.
Reporting of major harms in RCTs is sub-standard, not only
for HIV infection [32,33], making thorough meta-analyses
difﬁcult to perform. For example, only 48 of 98 RCTs
reported major adverse cardiovascular events, and, of these,
only 27 reported them in peer-reviewed publications,
including eight studies reporting only major adverse cardiac
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events leading to death. Similarly, only 52 of 98 trials
reported on cancers, with 32 reporting them in peer-re-
viewed publications, and only 15 of these reporting
arm-speciﬁc cancer outcomes not restricted to those leading
to death. Since 2008, 30 of 50 and 33 of 50 have reported
on major cardiovascular events and cancers, respectively.
Trial investigators place less importance on reporting
adverse events and potential major harms than on reporting
efﬁcacy. Better reporting of RCTs, longer follow-up of RCTs
and complementary observational data may help to improve
the amount and quality of evidence on potential major
clinical harms, particularly those that are emerging concerns
or rare.
As several pharmaceutical companies are apparently giving
consideration to sharing patient-level data from a number of
key RCTs, there will be opportunities to explore what patient
characteristics are associated with particular adverse events,
and whether the use of certain ARTs should be avoided within
some patient groups [34]. Improved opportunities for evi-
dence synthesis regarding harms may inform and improve
individualized and patient-centred treatments.
Guidelines have Surpassed Trial Data
Just as guidelines on what drugs to start treatment with have
changed over the years, so too have the guidelines on when
to start treatment (according to CD4 T-cell status or disease
stage). Because clinical progression rates are low when the
CD4 T-cell count remains at >200 cells/lL, but increase
rapidly at lower levels, most early treatment guidelines
advised that treatment be delayed until the CD4 cell count
had fallen to <200 cells/lL [35]. With time, however, this
threshold has increased. By 2008, most treatment guidelines
recommended that all individuals with a CD4 cell count of
<350 cells/lL should be treated [36,37]. In 2009–2011,
several studies attempted to examine when to start ART
by using cohort analyses [38–41]. All of the studies demon-
strated a cascade of mortality associated with lower CD4
status, but none conclusively identiﬁed a higher CD4
threshold for initiation than the existing guidelines. Subse-
quent guidelines from the IAS and varying WHO guidance
now support treatment initiation when the count is
>500 cells/lL [19,42]. Other country-speciﬁc guidance is
now supporting a test-and-treat approach regardless of CD4
status [43,44]. This is predominantly driven by the preventive
effects of ART in reducing infection of sexual partners [5].
Although this recommendation to treat patients early, so as
to reduce infectiousness and maintain health, is clearly
admirable, it is important to note that it is not based on
evidence from clinical trials, but rather from observational data
and expert opinion [45]. Of the only two RCTs evaluating
when to start ART, one from Haiti [46] examined whether
early treatment (at a CD4 count of >200 cells/lL but
<350 cells/lL) resulted in improved clinical outcomes relative
to waiting until the CD4 count fell to <200 cells/lL [46]. The
other study, from South Africa, examined early initiation with
ART among patients with concomitant tuberculosis [47]. A
large RCT that is currently enrolling, the START study, is
following patients randomized to immediate treatment
(>500 cells/lL) vs. deferring initiation of treatment until the
CD4 count falls to <350 cells/lL [48].
Almost all trials that we have identiﬁed included patients
with CD4 counts far below 500 cells/lL. Although we would
expect the drugs tested in these trials to show similar or
better effects in a healthier population, we do not know
much about their role within a healthier population. It is
possible that treatment effects or adverse events will differ in
some important ways. Future RCTs examining ART among
treatment-na€ıve patients will need to include healthier
populations. This means that they will rely even more
heavily upon surrogate outcomes and low rates of clinical
events, both efﬁcacy and adverse events. This will make the
evidence increasingly difﬁcult to interpret. Even meta-analy-
ses with a large number of trials may have substantial
residual uncertainty about the magnitude of treatment effects
for clinical outcomes.
How can we Improve the Evidence Base?
The ﬁeld of HIV/AIDS clinical trials is perhaps one of the most
successful and responsive ﬁelds in addressing new and innovative
therapies. It is, for the reasons that we outlined previously, also a
ﬁeld that can continue to improve. Coordinated clinical trials
groups, such as the AIDS Clinical Trials Group and the
International HIV Clinical Trials Group (INSIGHT), ensure that
RCTs have reliable methods and are performed in a reliable way,
but are also conservative in what treatments they wish to
evaluate. Industry often employs contract research organiza-
tions to conduct RCTs, and also try tomaintain high standards in
performing their trials. However, the questions asked need to
make clinical sense; for example, is the trial aiming to evaluate
non-inferiority or superiority, is the trial evaluating a class effect
or an individual drug, and will the trial be sufﬁciently powered
and of sufﬁcient duration to capture important adverse events?
Often, single trials will be unable to provide deﬁnitive answers to
most of these questions. Enabling single trials to belong to a
larger network of trials that can be seen as a growing network
meta-analysis is thus important.
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There is now a widespread call for drug companies and
others to deposit their individual-level data in open-access
portals for access by external researchers [34,49]. This will
allow opportunities for large-scale data synthesis to inform
guidelines and clinical practice. It seems unlikely that this will
occur for all trials conducted in the past, so investigators can
probably expect any future evaluations based on individ-
ual-level data to be based on a mix of individual-level data and
published data.
In conclusion, the ﬁeld of HIV/AIDS has made much
exciting progress in its therapeutics over time. However,
much of the clinical research conducted in this ﬁeld occurs in
a relatively uncoordinated way, such that the answers to
important questions regarding the superiority of some
combinations and the potential harms of well-established
ART are unknown.
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